Perspective Therapeutics

Perspective Therapeutics

Yahoo Finance • 6 days ago

Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor

SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers... Full story

Yahoo Finance • 8 days ago

Perspective Therapeutics (CATX) Reports Encouraging Early Data Across Multiple Radiopharmaceutical Trials

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. An expanding radiopharmaceutical pipeline, now stretching into a new brain tumor in... Full story

Yahoo Finance • last month

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers... Full story

Yahoo Finance • 2 months ago

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers th... Full story

Yahoo Finance • 2 months ago

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%

Key Points Avidity Partners added 259,700 shares of Enliven Therapeutics in the first quarter; the estimated transaction value was $7.19 million (based on quarterly average pricing). The quarter-end position value increased by $14.33 mill... Full story

Yahoo Finance • 3 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences

SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body,... Full story

Yahoo Finance • 4 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026VMT-α-NET study on tra... Full story

Yahoo Finance • 4 months ago

Perspective Therapeutics Q4 2025 Earnings Preview

* Perspective Therapeutics (CATX [https://seekingalpha.com/symbol/CATX]) is scheduled to announce Q4 earnings results on Monday, March 16th, after market close. * The consensus EPS Estimate is -$0.34 [https://seekingalpha.com/symbol/CA... Full story

Yahoo Finance • 5 months ago

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today... Full story

Yahoo Finance • 7 months ago

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics, Inc. SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for... Full story

Yahoo Finance • 7 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

SEATTLE, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, t... Full story

Yahoo Finance • 8 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Updated interim results from the Company’s [212Pb]VMT-α-NET Phase 1/2a study supporting the therapy’s compelling overall clinical profile at the 5 mCi dose were presented at the ESMO Congress 2025, NANETS and Triple meetingsEnrolled eight... Full story

Yahoo Finance • 9 months ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

SEATTLE, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body,... Full story

Yahoo Finance • 10 months ago

Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics, Inc. First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab [212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.... Full story

Yahoo Finance • 10 months ago

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today annou... Full story

Yahoo Finance • 11 months ago

Perspective Therapeutics to Participate in Upcoming September Conferences

SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announ... Full story

Yahoo Finance • 11 months ago

PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) Surpasses Q2 2025 Revenue Estimates with Narrower Loss

PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX [https://www.chartmill.com/stock/quote/CATX/profile]) reported its second-quarter 2025 financial results, delivering revenue that significantly surpassed analyst expectations while posting a narr... Full story

Yahoo Finance • 11 months ago

Perspective Therapeutics GAAP EPS of -$0.29 beats by $0.01, revenue of $0.29M beats by $0.12M

* Perspective Therapeutics press release [https://seekingalpha.com/pr/20199058-perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2025-results] (NYSE:CATX [https://seekingalpha.com/symbol/CATX]): Q2 GAAP EPS of -... Full story

Yahoo Finance • 11 months ago

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Tencent Holdings Limited (OTCPK:TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Stratasys Ltd. (SSYS [https://seekingalpha.com/symbol/SSYS]) * Organigram Global (OGI [... Full story

Yahoo Finance • 12 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

SEATTLE, July 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announc... Full story